Figure 1a




Figure 1b




Figure 2



HCC1187
Monoculture
CCL19 (pg/mL)
800
600
400
200
0
-20
-12
-10
-8
-6
Concentration [M]
Clone 1.9
Clone 1.10
Clone 1.11
Clone 1.12
BHA10

Figure 3a




Figure 3b




Figure 4



3000
2000
1000
0
MFI
-14
-12
-10
-8
-6
Concentration [M]
Clone 2.1
Clone 2.2
Clone 2.4
Clone 2.3
Clone 2.7
Clone 2.5
Clone 2.6

Figure 5a




Figure 5b




Figure 6



15000
10000
5000
0
MFI
-14
-12
-10
-8
-6
Concentration [M]
Clone 3.1
Clone 3.2
Clone 3.3
Clone 3.4

Figure 7

Figure 7a
1:1 Format




Figure 7b
2:1 Format




Figure 7c
2:2 Format




Figure 7d
2:2 Format




Figure 8a




Figure 8b




Figure 8c




Figure 8d




Figure 8e




Figure 8f




Figure 9a




Figure 9b




Figure 10a




Figure 10b




Figure 11a




Figure 11b




Figure 12a




Figure 12b




Figure 12c




Figure 12d




Figure 12e



8,000
6,000
4,000
2,000
0
mCCL5 (pg/mL)
0
-13
-12
-11
-10
-9
-8
-7
-6
Concentration [M]
P1AG5459
P1AG5461
Clone 4.14
Clone 4.14 +XL

Figure 13



ICAM1 Intensity /Cell
(Baseline subtracted)
2.00×10⁶
1.50×10⁶
1.00×10⁶
5.00×10⁵
0
0
-13
-12
-11
-10
-9
-8
-7
Concentration [M]
Clone 4.14
Clone 4.14 + XL
Clone 4.12
Clone 4.13

Figure 14



ICAM1 Intensity /Cell
(Baseline subtracted)
1500000
1000000
500000
0
-20
-12
-10
-8
-6
Concentration [M]
Clone 4.14
Clone 4.14 + XL
Clone 4.12
Clone 4.11

Figure 15



2000
1500
1000
500
0
Tumour volume (mm3)
10
15
20
25
30
Days post implantation
Isotype
CTLA-4
CTLA-4+10mg/kg Clone 4.14
CTLA-4+ Clone 4.11
**
*
****
***

Figure 16



Treatment schedule
PD-1
LTBR agonist
PD-1 +LTBR
Secondary tumor
IR
Primary tumor
Implantation
13
14
15
16
19
21
23
25
26
Radiotherapy (3 x 5Gy)
Clone 4.15 (10mg/kg i.p.)
Anti-PD-L1 (10mg/kg i.p., 10F.9G2)
Termination

Figure 17



MECA-79+%/CD31+ (HEV)
40
30
20
10
0
****
**
**
*
Isotype
CTLA-4
CTLA-4+Clone 4.14
CTLA-4+Clone 4.11

Figure 18



1500
1000
500
0
Tumour volume (mm3)
0
5
10
15
20
Days post implantation
***
Isotype
anti-PD-L1
Clone 4.11
anti-PD-L1+Clone 4.11

Figure 19a




Figure 19b




Figure 20



Isotype
PD-L1 Ab
PD-L1 Ab+Clone 4.11
Tumour volume (mm3)
1000
500
0
5
10
15
20
25
30
Days post implantation
***

Figure 21a




Figure 21b




Figure 21c




Figure 22a




Figure 22b




Figure 23a




Figure 23b




Figure 24



1500
1000
500
0
Tumour volume (mm3)
0
5
10
15
20
25
Days post implantation
***
RT
RT+ Clone 4.15
Clone 4.15

Figure 25



1500
1000
500
0
Tumour volume (mm3)
0
5
10
15
20
25
Days post implantation
*
RT
RT+ Clone 4.15
Clone 4.15

Figure 26a




Figure 26b




Figure 27a




Figure 27b




Figure 27c




Figure 27d




Figure 28a




Figure 28b




Figure 28c



Number of CD8+ T cells per mg tumour
CD8+/mg
140
120
100
80
60
40
20
0
****
***
Isotype
Clone 4.11
Peptide+adjuvant
Peptide+adjuvant+Clone 4.11

Figure 29




Isotype
Clone 4.11
Vaccine+Isotype
Vaccine+ Clone 4.11
** p=0.0023
Probability of survival
Days post implantation
Probability of Survival
100
50
0
0
10
20
30
40
50

Figure 30


Tumour growth
naive vs rechallenged mice
Naive
Rechallenged (vaccine mono) 2/2
Rechallenged (vaccine+clone 4.11) 7/7
Tumour volume (mm³)
2500
2000
1500
1000
500
0
0
10
20
30
40
50
60
70
80
Days post re-challange